{"id":"NCT00516139","sponsor":"GlaxoSmithKline","briefTitle":"Lamotrigine Extended-Release In Elderly Patients With Epilepsy","officialTitle":"Lamotrigine Extended-Release in Elderly Patients With Epilepsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2007-08-15","resultsPosted":"2012-01-13","lastUpdate":"2017-01-18"},"enrollment":122,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Lamotrigine","otherNames":[]}],"arms":[{"label":"Lamotrigine","type":"EXPERIMENTAL"}],"summary":"This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.","primaryOutcome":{"measure":"Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event","timeFrame":"From Baseline (Week 0) until 3 weeks after the end of treatment (Week 30 or 33)","effectByArm":[{"arm":"LTG-XR Tablets","deltaMin":22,"sd":null}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":63,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":121},"commonTop":["Dizziness","Balance disorder","Fall","Headache","Tremor"]}}